Global Prostate Cancer Diagnostics Revenue Is 10.01 Billion USD In 2017
Warning: date() expects parameter 2 to be long, string given in /www/wwwroot/www.globalinforesearch.com/static/themes/default/info_detail.php on line 32
In the last several years, global market of Prostate Cancer Diagnostics developed rapidly, with an average growth rate of 5.25%. In 2017, global revenue of Prostate Cancer Diagnostics is 10.01 billion USD.
The classification of Prostate Cancer Diagnostics includes Tumor Biomarker Tests, Imaging, Biopsy and other, and most of Prostate Cancer Diagnostics use the method of Biopsy, the proportion of Biopsy in 2017 is about 44.65%.
Prostate Cancer Diagnostics is widely used for the people with Prostate Cancer, The most proportion of Prostate Cancer Diagnostics is used for people with the age between 55 and 75, and the proportion is about 70.24% in 2017.
North America region is the largest region of Prostate Cancer Diagnostics, with a revenue market share nearly 49.84% in 2017. Europe is the second region of Prostate Cancer Diagnostics, enjoying revenue market share nearly 28% in 2017.
Market competition is intense. Genomic Health, Abbott, OPKO, Siemens Healthcare, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.